Recombinant human erythropoietin in the treatment of acute ischemic stroke

• Published in: Stroke (1970) Vol. 40; no. 12; p. e647
• Main Authors: Ehrenreich, Hannelore, Weissenborn, Karin, Prange, Hilmar, Schneider, Dietmar, Weimar, Christian, Wartenberg, Katja, Schellinger, Peter D, Bohn, Matthias, Becker, Harald, Wegrzyn, Martin, Jähnig, Peter, Herrmann, Manfred, Knauth, Michael, Bähr, Mathias, Heide, Wolfgang, Wagner, Armin, Schwab, Stefan, Reichmann, Heinz, Schwendemann, Günther, Dengler, Reinhard, Kastrup, Andreas, Bartels, Claudia
• Format: Journal Article
• Language: English
• Published: United States 01.12.2009
• Subjects: Acute Disease - therapy; Adult; Aged; Aged, 80 and over; Brain Ischemia - drug therapy; Brain Ischemia - physiopathology; Double-Blind Method; Drug Administration Schedule; Drug Interactions - physiology; Drug-Related Side Effects and Adverse Reactions; Erythropoietin - administration & dosage; Erythropoietin - adverse effects; Female; Humans; Infarction, Middle Cerebral Artery - drug therapy; Infarction, Middle Cerebral Artery - physiopathology; Injections, Intravenous; Male; Middle Aged; Mortality; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - adverse effects; Patient Selection; Placebo Effect; Recombinant Proteins - administration & dosage; Stroke - drug therapy; Stroke - physiopathology; Tissue Plasminogen Activator - administration & dosage; Tissue Plasminogen Activator - adverse effects; Treatment Outcome; Young Adult

Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment of patients with ischemic stroke. Although EPO has been considered to be a safe and well-tolerated drug over 2 decades, recen...